|
|
Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan
| Title: | Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan |
| Authors: | Kitagataya, Takashi Browse this author | | Suda, Goki Browse this author →KAKEN DB | | Nagashima, Kazunori Browse this author | | Katsurada, Takehiko Browse this author →KAKEN DB | | Yamamoto, Koji Browse this author →KAKEN DB | | Kimura, Megumi Browse this author | | Maehara, Osamu Browse this author | | Yamada, Ren Browse this author | | Shigesawa, Taku Browse this author | | Suzuki, Kazuharu Browse this author | | Nakamura, Akihisa Browse this author | | Ohara, Masatsugu Browse this author | | Umemura, Machiko Browse this author | | Kawagishi, Naoki Browse this author | | Nakai, Masato Browse this author | | Sho, Takuya Browse this author | | Natsuizaka, Mitsuteru Browse this author | | Morikawa, Kenichi Browse this author | | Ogawa, Koji Browse this author | | Ohnishi, Shunsuke Browse this author →KAKEN DB | | Komatsu, Yoshito Browse this author →KAKEN DB | | Hata, Hiroo Browse this author →KAKEN DB | | Takeuchi, Satoshi Browse this author | | Abe, Takashige Browse this author →KAKEN DB | | Sakakibara-Konishi, Jun Browse this author →KAKEN DB | | Teshima, Takanori Browse this author →KAKEN DB | | Homma, Akihiro Browse this author →KAKEN DB | | Sakamoto, Naoya Browse this author →KAKEN DB |
| Keywords: | adverse events | | female | | hepatitis | | immune checkpoint inhibitor | | immune system | | irAE | | risk factor |
| Issue Date: | Oct-2020 |
| Publisher: | John Wiley & Sons |
| Journal Title: | Journal of gastroenterology and hepatology |
| Volume: | 35 |
| Issue: | 10 |
| Start Page: | 1782 |
| End Page: | 1788 |
| Publisher DOI: | 10.1111/jgh.15041 |
| Abstract: | Background and Aim Immune checkpoint inhibitors (ICI) have revolutionized anti-malignancy therapy and thus have been increasingly used. Although ICI may cause immune-related adverse events (irAE) in various organs, including the liver, the prevalence and predictive factors of irAE have not been clarified. Methods In this retrospective study, consecutive patients who had malignancies and were treated with ICI without other chemotherapeutic agents at Hokkaido University Hospital between 2014 and 2019 were screened. Patients were excluded if they were Of the 233 patients screened, 202 patients met the inclusion criteria and were included in the analysis. The patients were aged 25-92 years, and 60.9% were male. The patients received nivolumab (n = 137), pembrolizumab (n = 45), ipilimumab (n = 17), atezolizumab (n = 2), and avelumab (n = 1). The prevalence of any grade and grade >= 3 irAE hepatitis was 8.4% (17/202) and 4.0% (8/202), respectively. irAE hepatitis occurred at a median duration of 42 days in any grade and 36 days in grade >= 3 after ICI initiation. The clinical course of grade >= 3 irAE hepatitis was generally favorable; however, 50% required corticosteroid treatment and two patients required additional mycophenolate mofetil. Female sex and history of ICI treatment were significantly associated with the incidence of grade >= 3 irAE hepatitis. Conclusions Grade >= 3 irAE hepatitis was observed in 4.0% of the patients who were treated with ICI. Female sex and history of ICI treatment were significantly associated with the incidence of grade >= 3 irAE hepatitis. |
| Rights: | This is the peer reviewed version of the following article: Kitagataya, T., Suda, G., Nagashima, K., Katsurada, T., Yamamoto, K., Kimura, M., Maehara, O., Yamada, R., Shigesawa, T., Suzuki, K., Nakamura, A., Ohara, M., Umemura, M., Kawagishi, N., Nakai, M., Sho, T., Natsuizaka, M., Morikawa, K., Ogawa, K., Ohnishi, S., Komatsu, Y., Hata, H., Takeuchi, S., Abe, T., Sakakibara‐Konishi, J., Teshima, T., Homma, A., and Sakamoto, N. (2020) Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy‐associated hepatitis in Japan. Journal of Gastroenterology and Hepatology, 35: 1782– 1788., which has been published in final form at https://doi.org/10.1111/jgh.15041. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/82884 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 北潟谷 隆
|
